RIO DE JANEIRO, BRAZIL - The National Health Regulatory Agency (Anvisa) received, on Monday (19), a request for emergency use of the drug Sotrovimab, a monoclonal antibody developed for the treatment of Covid-19. The request was submitted by the laboratory Glaxo Smith Kline.
The deadline for analyzing the request is 30 days, counting from the confirmation that all the necessary documents have been delivered. According to Anvisa, the drug has not had clinical studies conducted in Brazil so far.
UAE FINDS DRUG IS 100% SUCCESSFUL AT PREVENTING DEATHS
Between 30 . . .